AU2019274656A1 - Anti-CD3 antibodies and uses thereof - Google Patents
Anti-CD3 antibodies and uses thereof Download PDFInfo
- Publication number
- AU2019274656A1 AU2019274656A1 AU2019274656A AU2019274656A AU2019274656A1 AU 2019274656 A1 AU2019274656 A1 AU 2019274656A1 AU 2019274656 A AU2019274656 A AU 2019274656A AU 2019274656 A AU2019274656 A AU 2019274656A AU 2019274656 A1 AU2019274656 A1 AU 2019274656A1
- Authority
- AU
- Australia
- Prior art keywords
- antibody
- seq
- antigen
- antibodies
- nos
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Reproductive Health (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862676081P | 2018-05-24 | 2018-05-24 | |
| US62/676,081 | 2018-05-24 | ||
| PCT/IB2019/054188 WO2019224717A2 (en) | 2018-05-24 | 2019-05-21 | Anti-cd3 antibodies and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2019274656A1 true AU2019274656A1 (en) | 2020-11-26 |
Family
ID=67211773
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2019274656A Pending AU2019274656A1 (en) | 2018-05-24 | 2019-05-21 | Anti-CD3 antibodies and uses thereof |
Country Status (38)
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL319047A (en) | 2015-08-28 | 2025-04-01 | Amunix Operating Inc | Chimeric polypeptide composition and methods for its preparation and use |
| WO2018119142A1 (en) | 2016-12-21 | 2018-06-28 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| CN118994394A (zh) | 2017-06-12 | 2024-11-22 | 蓝鳍生物医药公司 | 抗-il1rap抗体和抗体药物缀合物 |
| JOP20200303A1 (ar) | 2018-05-24 | 2020-11-23 | Janssen Biotech Inc | عوامل ربط psma واستخداماتها |
| CR20200564A (es) | 2018-05-24 | 2021-06-21 | Janssen Biotech Inc | Anticuerpos anti-tmeff2 monoespecificos y multiespecificos y sus usos |
| JOP20190116A1 (ar) * | 2018-05-24 | 2019-11-24 | Janssen Biotech Inc | الأجسام المضادة لتكتل التمايز 33 (cd33)، والأجسام المضادة ثنائية النوعية لتكتل التمايز 33 (cd33)/تكتل التمايز 3 (cd3) واستخداماتها |
| SMT202400102T1 (it) | 2018-07-19 | 2024-05-14 | Regeneron Pharma | Recettori chimerici dell’antigene con specificità per bcma e loro usi |
| TWI838389B (zh) * | 2018-07-19 | 2024-04-11 | 美商再生元醫藥公司 | 雙特異性抗-BCMAｘ抗-CD3抗體及其用途 |
| CA3136888A1 (en) | 2019-04-19 | 2020-10-22 | Janssen Biotech, Inc. | Methods of treating prostate cancer with an anti- psma/cd3 antibody |
| NZ785553A (en) * | 2019-07-26 | 2025-07-25 | Janssen Biotech Inc | Proteins comprising kallikrein related peptidase 2 antigen binding domains and their uses |
| EP4076523A1 (en) * | 2019-12-18 | 2022-10-26 | Janssen Biotech, Inc. | Materials and methods for in vivo biological targeting |
| AU2021225870A1 (en) * | 2020-02-27 | 2022-10-20 | Janssen Biotech, Inc. | Materials and methods for modulating an immune response |
| US20210284731A1 (en) * | 2020-03-13 | 2021-09-16 | Janssen Biotech, Inc. | Methods and materials for modulating an immune response |
| KR20230017841A (ko) | 2020-05-27 | 2023-02-06 | 얀센 바이오테크 인코포레이티드 | Cd3 항원 결합 도메인을 포함하는 단백질 및 이의 용도 |
| JP2023536818A (ja) | 2020-07-29 | 2023-08-30 | ヤンセン バイオテツク，インコーポレーテツド | Ｈｌａ－ｇ抗原結合ドメインを含むタンパク質及びそれらの使用 |
| JP2023539525A (ja) * | 2020-09-02 | 2023-09-14 | ジェンマブ エー／エス | 抗体療法 |
| CA3194771A1 (en) | 2020-09-16 | 2022-03-24 | Amgen Inc. | Methods for administering therapeutic doses of bispecific t-cell engaging molecules for the treatment of cancer |
| EP4223777A4 (en) * | 2020-09-29 | 2025-01-08 | Fortvita Biologics (Singapore) Pte. Ltd. | ANTI-CD3 ANTIBODY AND ITS USES |
| KR20230110523A (ko) | 2020-10-22 | 2023-07-24 | 얀센 바이오테크 인코포레이티드 | 델타-유사 리간드 3(dll3) 항원 결합 영역을 포함하는 단백질 및 그의 용도 |
| CA3211163A1 (en) * | 2021-02-16 | 2022-08-25 | Janssen Pharmaceutica Nv | Trispecific antibody targeting bcma, gprc5d, and cd3 |
| EP4341290A1 (en) | 2021-05-21 | 2024-03-27 | LEO Pharma A/S | Anti il-1 receptor accessory protein antibodies |
| US20230073821A1 (en) * | 2021-08-27 | 2023-03-09 | International Business Machines Corporation | Antigen-binding proteins targeting coronavirus (cov) variants |
| AU2022333321A1 (en) * | 2021-08-27 | 2024-04-11 | Janssen Biotech, Inc. | Anti-psma antibodies and uses thereof |
| US20250346668A1 (en) * | 2022-03-25 | 2025-11-13 | Genor Biopharma Co., Ltd | Cd3-targeting antibody and use thereof |
| WO2024062074A1 (en) | 2022-09-21 | 2024-03-28 | Sanofi Biotechnology | Humanized anti-il-1r3 antibody and methods of use |
| WO2024077044A1 (en) | 2022-10-05 | 2024-04-11 | Amgen Inc. | Combination therapies comprising t-cell redirecting therapies and agonistic anti-il-2r antibodies or fragments thereof |
| WO2024089551A1 (en) | 2022-10-25 | 2024-05-02 | Janssen Biotech, Inc. | Msln and cd3 binding agents and methods of use thereof |
| WO2024126833A1 (en) * | 2022-12-16 | 2024-06-20 | Ichnos Sciences SA | Cd47-il1rap bispecific antibodies |
| WO2025134050A1 (en) | 2023-12-21 | 2025-06-26 | Janssen Biotech, Inc | Trispecific antibody targeting bcma, gprc5d and cd3 for the treatment of multiple myeloma |
| WO2025134049A1 (en) | 2023-12-21 | 2025-06-26 | Janssen Biotech, Inc | Trispecific antibody targeting bcma, gprc5d and cd3 for the treatment of al amyloidosis |
| WO2025217101A2 (en) | 2024-04-09 | 2025-10-16 | Amgen Inc. | Agonistic anti-il-2rbg heavy‑chain antibodies |
| WO2025230233A1 (ko) * | 2024-05-03 | 2025-11-06 | 국민대학교산학협력단 | 인간 cd3에 특이적인 항체 및 이의 용도 |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| ATE87659T1 (de) | 1986-09-02 | 1993-04-15 | Enzon Lab Inc | Bindungsmolekuele mit einzelpolypeptidkette. |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
| DE122004000008I1 (de) | 1991-06-14 | 2005-06-09 | Genentech Inc | Humanisierter Heregulin Antikörper. |
| ES2227512T3 (es) | 1991-12-02 | 2005-04-01 | Medical Research Council | Produccion de anticuerpos contra auto-antigenos a partir de repertorios de segmentos de anticuerpos fijados en un fago. |
| ATE199392T1 (de) | 1992-12-04 | 2001-03-15 | Medical Res Council | Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung |
| AUPO591797A0 (en) | 1997-03-27 | 1997-04-24 | Commonwealth Scientific And Industrial Research Organisation | High avidity polyvalent and polyspecific reagents |
| WO1999014318A1 (en) | 1997-09-16 | 1999-03-25 | Board Of Regents, The University Of Texas System | Method for the complete chemical synthesis and assembly of genes and genomes |
| US6670127B2 (en) | 1997-09-16 | 2003-12-30 | Egea Biosciences, Inc. | Method for assembly of a polynucleotide encoding a target polypeptide |
| US6818749B1 (en) | 1998-10-31 | 2004-11-16 | The United States Of America As Represented By The Department Of Health And Human Services | Variants of humanized anti carcinoma monoclonal antibody cc49 |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| ES2405944T3 (es) | 2000-11-30 | 2013-06-04 | Medarex, Inc. | Ácidos nucleicos que codifican las secuencias de inmunoglobulina humana reorganizadas a partir de ratones transcromoscómicos transgénicos zadas |
| MXPA05000511A (es) | 2001-07-12 | 2005-09-30 | Jefferson Foote | Anticuepros super humanizados. |
| JP2008511337A (ja) | 2004-09-02 | 2008-04-17 | ジェネンテック・インコーポレーテッド | ヘテロ多量体分子 |
| DK3050963T3 (da) | 2005-03-31 | 2019-12-09 | Chugai Pharmaceutical Co Ltd | Fremgangsmåde til fremstilling af polypeptid ved regulering af arrangement |
| DE102005028778A1 (de) | 2005-06-22 | 2006-12-28 | SUNJÜT Deutschland GmbH | Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage |
| EP1999154B1 (en) | 2006-03-24 | 2012-10-24 | Merck Patent GmbH | Engineered heterodimeric protein domains |
| EP2035456A1 (en) | 2006-06-22 | 2009-03-18 | Novo Nordisk A/S | Production of bispecific antibodies |
| US20090155275A1 (en) | 2007-07-31 | 2009-06-18 | Medimmune, Llc | Multispecific epitope binding proteins and uses thereof |
| US8748356B2 (en) | 2007-10-19 | 2014-06-10 | Janssen Biotech, Inc. | Methods for use in human-adapting monoclonal antibodies |
| AU2008343589A1 (en) | 2007-12-19 | 2009-07-09 | Centocor Ortho Biotech Inc. | Design and generation of human de novo pIX phage display libraries via fusion to pIX or pVII, vectors, antibodies and methods |
| US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
| US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
| US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
| US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
| JP2012505654A (ja) | 2008-10-14 | 2012-03-08 | ヤンセン バイオテツク，インコーポレーテツド | 抗体をヒト化及び親和性成熟する方法 |
| EP2424567B1 (en) | 2009-04-27 | 2018-11-21 | OncoMed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
| PL2560993T3 (pl) | 2010-04-20 | 2024-11-04 | Genmab A/S | Heterodimeryczne białka zawierające region FC przeciwciała i sposoby ich wytwarzania |
| RS59589B1 (sr) | 2010-11-05 | 2019-12-31 | Zymeworks Inc | Dizajniranje stabilnog heterodimernog antitela sa mutacijama u fc domenu |
| EA033677B1 (ru) | 2011-05-21 | 2019-11-15 | Macrogenics Inc | Cd3-связывающие молекулы, способные к связыванию с cd3 человека и cd3, не являющимся человеческим |
| WO2013063702A1 (en) | 2011-11-04 | 2013-05-10 | Zymeworks Inc. | Stable heterodimeric antibody design with mutations in the fc domain |
| JOP20200236A1 (ar) * | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| KR20220041953A (ko) | 2012-12-14 | 2022-04-01 | 오픈 모노클로날 테크놀로지, 인코포레이티드 | 인간 이디오타입을 갖는 설치류 항체를 인코딩하는 폴리뉴클레오티드 및 이를 포함하는 동물 |
| MX373245B (es) * | 2013-07-05 | 2020-05-11 | Genmab As | Anticuerpos cd3 humanizados o quiméricos. |
| EP3736292B1 (en) * | 2013-12-17 | 2024-05-08 | Genentech, Inc. | Anti-cd3 antibodies and methods of use |
| CN106459201A (zh) * | 2014-05-28 | 2017-02-22 | 豪夫迈·罗氏有限公司 | 结合人和食蟹猴CD3ε的抗体 |
| EP2982693A1 (en) * | 2014-08-07 | 2016-02-10 | Affimed Therapeutics AG | CD3 binding domain |
| LT3247725T (lt) * | 2015-01-23 | 2020-10-12 | Sanofi | Anti-cd3 antikūnai, anti-cd123 antikūnai ir bispecifiniai antikūnai, specifiškai surišantys cd3 ir (arba) cd123 |
| EA201891084A1 (ru) | 2015-11-02 | 2019-10-31 | Антитела к il1rap, биспецифические антигенсвязывающие молекулы, которые связываются с il1rap и cd3, и их применение | |
| MY200988A (en) | 2016-09-14 | 2024-01-27 | Teneobio Inc | CD3 Binding Antibodies |
| MX2020012286A (es) * | 2018-05-16 | 2021-04-28 | Janssen Biotech Inc | Metodos para tratar canceres y potenciar la eficacia de agentes terapeuticos para el redireccionamiento de celulas t. |
| CR20200564A (es) * | 2018-05-24 | 2021-06-21 | Janssen Biotech Inc | Anticuerpos anti-tmeff2 monoespecificos y multiespecificos y sus usos |
| JOP20190116A1 (ar) | 2018-05-24 | 2019-11-24 | Janssen Biotech Inc | الأجسام المضادة لتكتل التمايز 33 (cd33)، والأجسام المضادة ثنائية النوعية لتكتل التمايز 33 (cd33)/تكتل التمايز 3 (cd3) واستخداماتها |
| JOP20200303A1 (ar) | 2018-05-24 | 2020-11-23 | Janssen Biotech Inc | عوامل ربط psma واستخداماتها |
-
2019
- 2019-05-21 JP JP2020565282A patent/JP7530299B2/ja active Active
- 2019-05-21 WO PCT/IB2019/054188 patent/WO2019224717A2/en not_active Ceased
- 2019-05-21 HR HRP20250621TT patent/HRP20250621T1/hr unknown
- 2019-05-21 CA CA3101271A patent/CA3101271A1/en active Pending
- 2019-05-21 BR BR112020023508-3A patent/BR112020023508A2/pt unknown
- 2019-05-21 HU HUE19737219A patent/HUE072251T2/hu unknown
- 2019-05-21 UA UAA202008271A patent/UA129050C2/uk unknown
- 2019-05-21 CR CR20200568A patent/CR20200568A/es unknown
- 2019-05-21 CN CN202510209510.8A patent/CN120058941A/zh active Pending
- 2019-05-21 EA EA202092847A patent/EA202092847A1/ru unknown
- 2019-05-21 EP EP19737219.6A patent/EP3802608B1/en active Active
- 2019-05-21 CN CN201980049271.7A patent/CN112912397B/zh active Active
- 2019-05-21 RS RS20250579A patent/RS66901B1/sr unknown
- 2019-05-21 AU AU2019274656A patent/AU2019274656A1/en active Pending
- 2019-05-21 PL PL19737219.6T patent/PL3802608T3/pl unknown
- 2019-05-21 MA MA52773A patent/MA52773B1/fr unknown
- 2019-05-21 SM SM20250221T patent/SMT202500221T1/it unknown
- 2019-05-21 US US16/418,082 patent/US11603405B2/en active Active
- 2019-05-21 PE PE2020001886A patent/PE20210132A1/es unknown
- 2019-05-21 FI FIEP19737219.6T patent/FI3802608T3/fi active
- 2019-05-21 ES ES19737219T patent/ES3032856T3/es active Active
- 2019-05-21 PT PT197372196T patent/PT3802608T/pt unknown
- 2019-05-21 SI SI201930938T patent/SI3802608T1/sl unknown
- 2019-05-21 SG SG11202011270QA patent/SG11202011270QA/en unknown
- 2019-05-21 JO JOP/2020/0302A patent/JOP20200302A1/ar unknown
- 2019-05-21 DK DK19737219.6T patent/DK3802608T3/da active
- 2019-05-21 KR KR1020207037046A patent/KR20210012007A/ko active Pending
- 2019-05-21 MX MX2020012587A patent/MX420253B/es unknown
- 2019-05-21 LT LTEPPCT/IB2019/054188T patent/LT3802608T/lt unknown
- 2019-05-21 EP EP25173398.6A patent/EP4643951A2/en active Pending
- 2019-05-24 UY UY0001038245A patent/UY38245A/es unknown
- 2019-05-24 AR ARP190101400A patent/AR115422A1/es unknown
- 2019-05-24 TW TW108118086A patent/TW202012443A/zh unknown
-
2020
- 2020-11-09 PH PH12020551920A patent/PH12020551920A1/en unknown
- 2020-11-19 IL IL278846A patent/IL278846A/en unknown
- 2020-11-23 CL CL2020003033A patent/CL2020003033A1/es unknown
- 2020-11-23 CO CONC2020/0014506A patent/CO2020014506A2/es unknown
- 2020-11-23 NI NI202000089A patent/NI202000089A/es unknown
- 2020-11-23 EC ECSENADI202075215A patent/ECSP20075215A/es unknown
- 2020-11-24 SA SA520420631A patent/SA520420631B1/ar unknown
-
2023
- 2023-03-08 US US18/180,225 patent/US20230322924A1/en active Granted
-
2024
- 2024-05-29 JP JP2024087232A patent/JP2024116190A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230322924A1 (en) | Anti-cd3 antibodies and uses thereof | |
| JP7603578B2 (ja) | 多価抗体 | |
| AU2015341884B2 (en) | CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production | |
| JP7292200B2 (ja) | 抗ｇｐｒｃ５ｄ抗体、ｇｐｒｃ５ｄとｃｄ３を結合する二重特異性抗原結合分子、及びその使用 | |
| JP2023051968A (ja) | 多重特異的ＮＫｐ４６結合タンパク質 | |
| CA2966566A1 (en) | Combination therapy of t cell activating bispecific antigen binding molecules cd3 and folate receptor 1 (folr1) and pd-1 axis binding antagonists | |
| US20240059789A1 (en) | Psma binding proteins and uses thereof | |
| TWI865451B (zh) | 單特異性及多特異性抗ｔｍｅｆｆ２抗體及其用途 | |
| US20190135918A1 (en) | Cd3/cd38 t cell retargeting hetero-dimeric immunoglobulins and methods of their production | |
| TW202216767A (zh) | 與ＣＤ３及ＦｏｌＲ１結合之抗體 | |
| TW202521579A (zh) | 經穩定化之ｃｄ３抗原結合劑及其使用方法 | |
| HK40052977A (en) | Anti-cd3 antibodies and uses thereof | |
| EA045935B1 (ru) | Антитела к cd3 и их применение | |
| TW202539744A (zh) | 抗ｃｅａｃａｍ５抗體藥物軛合物 |